載入中
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.
一般交易時段
US$13.5426
−US$0.2274 · -1.65%
盤中時間採用ET。市場資料可能有所延遲。
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.
日內區間
目前US$13.5426
52週區間
目前US$13.5426
盤中時間採用ET。市場資料可能有所延遲。
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.
日內區間
目前US$13.5426
52週區間
目前US$13.5426
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | — | 28.2萬 USD | 9.6萬 USD | 6.8萬 USD | 1.5萬 USD |
| 毛利 | — | −28.2萬 USD | −9.6萬 USD | −6.8萬 USD | −1.5萬 USD |
| 研究與開發 | 9312.1萬 USD | 5318.7萬 USD | 6421.9萬 USD | 3862.2萬 USD | 1498.7萬 USD |
| 銷售、一般及管理費用 | 2042.1萬 USD | 2112.7萬 USD | 1709.4萬 USD | 1454.7萬 USD | 802萬 USD |
| 營業費用 | 1.14億 USD | 7431.4萬 USD | 8131.3萬 USD | 5316.9萬 USD | 2300.7萬 USD |
| 利息收入 | 778.2萬 USD | 504.2萬 USD | 594.5萬 USD | 183萬 USD | 6.5萬 USD |
| 折舊和攤銷 | 2.6萬 USD | 28.2萬 USD | 9.6萬 USD | 6.8萬 USD | 1.5萬 USD |
| 營業利益 | −1.14億 USD | −7459.6萬 USD | −8140.9萬 USD | −5323.7萬 USD | −2302.2萬 USD |
| 淨利 | −1.27億 USD | −6962.8萬 USD | −7552.1萬 USD | −5151.1萬 USD | −2296.3萬 USD |
公司資料更新於 2026年10月8日。
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$47.83
上漲空間 253.18%評級樣本有限，僅4項
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
